Search research articles
Contact Us
Filters
Showing results (71-80 of 89) with videos related to
Page
of 9
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2003
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice
Gobalakrishnan Sundaresan, Paul J Yazaki, John E Shively, et al.
Protein Engineering, Design & Selection : PEDS
|
June 10, 2004
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
Tove Olafsen, Giselle J Tan, Chia-Wei Cheung, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 17, 2013
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET
Joanne E Mortimer, James R Bading, David M Colcher, et al.
Protein Engineering, Design & Selection : PEDS
|
February 27, 2004
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications
Tove Olafsen, Chia-Wei Cheung, Paul J Yazaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
G A Wiseman, C A White, T E Witzig, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
May 19, 2006
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies
Jeffrey Y C Wong, David Z Chu, Lawrence E Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
T E Witzig, C A White, G A Wiseman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer
J Y Wong, G Somlo, T Odom-Maryon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 23, 2017
Tumor Uptake of <sup>64</sup>Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
Joanne E Mortimer, James R Bading, Jinha M Park, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 1999
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution
J A Carrasquillo, J D White, C H Paik, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 89) with videos related to
Sort By:
Page
of 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2003
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice
Gobalakrishnan Sundaresan, Paul J Yazaki, John E Shively, et al.
Protein Engineering, Design & Selection : PEDS
|
June 10, 2004
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
Tove Olafsen, Giselle J Tan, Chia-Wei Cheung, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 17, 2013
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET
Joanne E Mortimer, James R Bading, David M Colcher, et al.
Protein Engineering, Design & Selection : PEDS
|
February 27, 2004
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications
Tove Olafsen, Chia-Wei Cheung, Paul J Yazaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
G A Wiseman, C A White, T E Witzig, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
May 19, 2006
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies
Jeffrey Y C Wong, David Z Chu, Lawrence E Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
T E Witzig, C A White, G A Wiseman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer
J Y Wong, G Somlo, T Odom-Maryon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 23, 2017
Tumor Uptake of <sup>64</sup>Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
Joanne E Mortimer, James R Bading, Jinha M Park, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 1999
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution
J A Carrasquillo, J D White, C H Paik, et al.
Page
of 9